BioSpace News Archive

The Clarisolve mPAA polymer is a stimulus-responsive flocculation polymer designed specifically to enable a simpler clarification of high density cell culture monoclonal antibody (mAb) processes, and provides an alternative to centrifugation for these challenging bioreactor harvests when used in combination with Clarisolve® depth filters.

The expansion will transform the Columbus-East facility into the flagship plastic injection molding manufacturing facility for BD.

A new study published in PLOS ONE demonstrates that Videssa Breast, a multi-protein biomarker blood test for breast cancer by Provista Diagnostics, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

CARMAT announces that the first international implantation of its bioprosthetic artificial heart has been performed at the National Research Center for Cardiac Surgery (Astana, Kazakhstan) in accordance with the protocol of the PIVOTAL study.

The conference call will follow the anticipated release of the company’s financial results earlier that day.

The new shares are expected to be registered with the Finnish Trade Register on or about 30 October 2017.

The company has selected TAMM Net as FDA consultant to lead regulatory actions for USF treatment.

Nexeon announced its completion of an initial series of clinical studies evaluating the utilization of transcutaneous auricular vagus nerve stimulation (aVNS) for the relief of paroxysmal atrial fibrillation.

Dr. Fuchs is an internationally recognized expert in gastrointestinal cancers, cancer epidemiology and cancer drug development.

Sunesis anticipates using the net proceeds from the proposed offerings to fund the continued development of their pipeline.